Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 5/20 | 0.37 |
| ▸ | PRKAG1 | P54619 | 5/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 5/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 0.37 |
| ▸ | PRKAG3 | Q9UGI9 | 5/20 | 0.37 |
| ▸ | PRKAG2 | Q9UGJ0 | 5/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 5/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17384876 | 0.91 | PARP1 (0.51) | MAP4K4PARP1DPP4HDAC1NR1H2 | |
| SCHEMBL16333441 | 0.87 | MAP4K4 (0.57) | MAP4K4DPP4HDAC1NR1H2NR1H3 | |
| SCHEMBL16333318 | 0.80 | MAP4K4 (0.53) | MAP4K4POLBTDP1CKS1BSKP1 | |
| SCHEMBL19096970 | 0.80 | BTK (0.40) | PARP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL17375391 | 0.80 | BTK (0.40) | PARP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL38664017 | 0.78 | PARP1 (0.48) | MAP4K4PARP1DPP4HDAC1NR1H2 | |
| SCHEMBL38665849 | 0.78 | PARP1 (0.48) | MAP4K4PARP1DPP4HDAC1NR1H2 | |
| SCHEMBL38665068 | 0.78 | MAP4K4 (0.46) | MAP4K4PARP1DPP4HDAC1NR1H2 | |
| SCHEMBL38664483 | 0.78 | MAP4K4 (0.46) | MAP4K4PARP1DPP4HDAC1NR1H2 | |
| SCHEMBL21070521 | 0.75 | HDAC1 (0.56) | MAP4K4PARP1DPP4HDAC1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160967-B1 | N-(IMIDAZO[1,2-A]PYRAZIN-6-YL)-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-9975900-B2 | Substituted imidazo[1,2-α]pyrazines for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2017-07-13 | — | — | US | disclosed |
| EP-3160967-A1 | IMIDAZO[1,2-A]PYRAZIN-1YL-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015197503-A1 | IMIDAZO[1,2-A]PYRAZIN-1YL-BENZAMIDE COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197969-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, PYGM, GYS1 | MAP4K4 4379/4885PARP1 2340/4885DPP4 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.